Thapa B, Caimi PF, Ardeshna KM, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020;4(16):3850-3852.

相似書籍

• CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy
  由: Thapa, Bicky, et al.
  出版: (2020)
• CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed/Refractory DLBCL
  出版: (2020)
• Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
  由: Tabbara, Nadeem, et al.
  出版: (2021)
• CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
  由: Liang, Yun, et al.
  出版: (2021)
• Lee AYY. The changing landscape of anticoagulation in cancer-associated thrombosis. Blood Adv. 2020;4(5):969.
  出版: (2020)